Search Orphan Drug Designations and Approvals
-
Generic Name: | 1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl] ethanone |
---|---|
Date Designated: | 01/03/2023 |
Orphan Designation: | Treatment of Stage IIB to Stage IV Melanoma |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Linnaeus Therapeutics, Inc. 30 Washington Avenue, Suite F Haddonfield, New Jersey 08033 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-